BioCentury | Aug 27, 2014
Company News

Biogen Idec hires Johns as VP of new ALS unit

...3, 2013) . Early last year, Biogen discontinued development of its prior lead ALS compound, dexpramipexole...
BioCentury | Oct 3, 2013
Targets & Mechanisms

Alternative strategies in ALS

...molecules involved in axonal degeneration of motor neurons. In January, Biogen Idec discontinued development of dexpramipexole...
...Knopp Biosciences LLC after showing a dose-dependent reduction in disease progression in Phase II trials. Dexpramipexole...
...gene associated with about 20% of familial cases. However, the precise mechanism of action of dexpramipexole...
BioCentury | Jun 24, 2013
Company News

Knopp Biosciences, Prize4Life Inc. neurology news

...data from 468 patients in the placebo arm in the Phase III EMPOWER trial evaluating dexpramipexole...
...to contribute the treatment arm data from EMPOWER to PRO-ACT following the completion of future dexpramipexole...
...Inc. (NASDAQ:BIIB, Weston, Mass.), which has exclusive, worldwide rights from Knopp to develop and commercialize dexpramipexole...
BioCentury | Apr 1, 2013
Finance

1Q Stock Wrap-Up: Out fast at opening bell

...NASDAQ:BIIB)/Knopp Biosciences LLC Biogen discontinues development of dexpramipexole for amyotrophic lateral sclerosis (ALS) after twice-daily dexpramipexole...
BioCentury | Mar 11, 2013
Company News

Biogen Idec, Knopp Biosciences neurology news

...plasma samples were collected as part of the Phase III EMPOWER trial, which was evaluating dexpramipexole...
...develop and commercialize the compound under a 2010 deal. In January, Biogen discontinued development of dexpramipexole...
...could not be reached for comment. A trial is scheduled to start on June 17. Dexpramipexole...
BioCentury | Mar 11, 2013
Finance

Highlights of weekly biotech stock moves

...plasma samples were collected as part of the Phase III EMPOWER trial, which was evaluating dexpramipexole...
...treat ALS. Biogen Idec, which has rights to the compound from Knopp, discontinued development of dexpramipexole...
BioCentury | Mar 9, 2013
Company News

Knopp suing Biogen over ALS biosamples

...plasma samples were collected as part of the Phase III EMPOWER trial, which was evaluating dexpramipexole...
...and commercialize the compound under a 2010 deal. In January, Biogen Idec discontinued development of dexpramipexole...
...could not be reached for comment. A trial is scheduled to start on June 17. Dexpramipexole...
BioCentury | Jan 21, 2013
Product Development

Solving the ALS maze

...trials. ALS companies, advocacy organizations and patients had high hopes that Biogen Idec Inc. 's dexpramipexole...
...trends of functional improvement seen in Phase II. But on Jan. 3, Biogen Idec said dexpramipexole...
...for 300 mg dexpramipexole vs. 30% for placebo (p=0.028 for the trend). Biogen Idec in-licensed dexpramipexole...
BioCentury | Jan 7, 2013
Clinical News

Dexpramipexole: Development discontinued

...Biogen Idec discontinued development of dexpramipexole after top-line data from the double-blind, international Phase III EMPOWER...
...double-blind, international Phase III EMPOWER trial in 943 ALS patients showed that twice-daily 150 mg dexpramipexole...
...change in CAFS scores from baseline to 12 months vs. placebo. The company also said dexpramipexole...
BioCentury | Jan 7, 2013
Analyst Picks & Changes

Analyst picks & changes

...Butler lowered his target to $145 from $150 after Biogen Idec discontinued development of twice-daily dexpramipexole...
...not disclose a date. Somaiya also lowered his target to $166 from $175 on the dexpramipexole...
Items per page:
1 - 10 of 28